Hennion & Walsh Asset Management’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
– Sell
-1,891
Closed -$259K – 921
2025
Q1
$259K Sell
1,891
-192
-9% -$27.4K 0.01% 786
2024
Q4
$319K Sell
2,083
-3,430
-62% -$579K 0.01% 741
2024
Q3
$1.07M Sell
5,513
-1,277
-19% -$267K 0.05% 439
2024
Q2
$1.57M Sell
6,790
-184
-3% -$40K 0.08% 310
2024
Q1
$1.5M Sell
6,974
-93
-1% -$21.8K 0.08% 317
2023
Q4
$1.83M Buy
7,067
+319
+5% +$78.4K 0.1% 260
2023
Q3
$1.73M Buy
6,748
+1,573
+30% +$421K 0.11% 237
2023
Q2
$1.47M Buy
5,175
+2,709
+110% +$806K 0.09% 283
2023
Q1
$686K Buy
2,466
+376
+18% +$104K 0.04% 436
2022
Q4
$579K Buy
+2,090
New +$590K 0.04% 467
2022
Q2
– Sell
-1,095
Closed -$231K – 761
2022
Q1
$231K Sell
1,095
-563
-34% -$122K 0.01% 711
2021
Q4
$398K Sell
1,658
-462
-22% -$119K 0.02% 591
2021
Q3
$600K Buy
2,120
+103
+5% +$33.8K 0.03% 467
2021
Q2
$698K Sell
2,017
-338
-14% -$102K 0.04% 443
2021
Q1
$659K Buy
+2,355
New +$635K 0.04% 449

Other funds holding BIIB

Hennion & Walsh Asset Management's BIIB Position: Q2 2025 in Review

Hennion & Walsh Asset Management sold out of Biogen (BIIB) in Q2 2025, closing a stake of 1,891 shares — an estimated $259K sold.

Hennion & Walsh Asset Management first reported a position in BIIB in Q1 2021 and held it in 15 quarters. The position peaked at $1.83M in Q4 2023. 866 funds tracked by Wall St. Rank hold BIIB as of Q2 2025.

  • Hennion & Walsh Asset Management reported no remaining Biogen position as of Q2 2025 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 1,891 Biogen shares in Q2 2025, an estimated $259K.
  • Hennion & Walsh Asset Management first reported a position in Biogen in Q1 2021 and held it in 15 quarters.
  • Hennion & Walsh Asset Management's Biogen position peaked at $1.83M in Q4 2023.
  • 866 funds tracked by Wall St. Rank held Biogen as of Q2 2025.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.